Lonza Group AG

Three-program alliance with Synaffix reflects SOTIO’s commitment to further broaden and advance innovative ADC pipeline PRAGUE, Czech Republic & AMSTERDAM, The Netherlands I March 13, 2025 I SOTIO Biotech , a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will be exercising its option, under its license and option agreement with Synaffix B.V. (“Synaffix”), a Lonza company (SWX: LONN), to obtain a license to Synaffix’s technology to develop two bispecific antibody-drug conjugate (ADC) programs. The exercised option will enable SOTIO to advance two bispecific candidates, designed by its in-house research team, that have the potential to become first-in-class and/or best-in-class treatments for solid tumors. SOT112 is a bispecific ADC with potential applicability in several major cancer indications, while SOT113 demonstrates promise for precision targeting of prostate cancer. Both programs leverage the selection of highly attractive target pairs and are now in the lead nomination stage. The bispecific antibody candidates were identified by SOTIO’s research team and will now be developed under SOTIO’s license and option agreement with Synaffix, which enables SOTIO to combine its proprietary antibodies with Synaffix’s GlycoConnect ® , HydraSpace ® , and potent linker-payloads of the toxSYN ® platform to research, develop, manufacture, and commercialize ADC products. “The promising preclinical data on SOT112 and SOT113 have reinforced our confidence in their potential, and we are excited to advance these candidates within our first-in-class and best-in-class ADC portfolio,” said Martin Steegmaier, Ph.D., chief scientific officer of SOTIO. “Bispecific ADCs represent a groundbreaking frontier in oncology, offering enhanced tumor-targeting precision and the potential to overcome the challenges of heterogeneity in solid tumor target expression. Both advancements align with our mission to develop safer and more effective treatments for solid tumors.” Peter van de Sande, head of Synaffix, commented: “We are pleased that SOTIO, recognizing the versatility and robustness of our clinically validated platform, has chosen to expand its use of our ADC technology to two additional targets. ADCs are a key part of our offering, and our technology is primed to support this next stage of innovation in targeted cancer therapeutics. We look forward to seeing these promising candidates advance toward the clinic.” Under the terms of the agreement, Synaffix is eligible to receive an upfront payment with the potential for milestone payments, plus single-digit royalties on net sales. SOTIO will be responsible for research, development, manufacturing, and commercialization of the ADC products, and Synaffix will closely support SOTIO’s research activities and be responsible for the manufacturing of components that are specifically related to its proprietary GlycoConnect ® , HydraSpace ® , and linker-payloads of the toxSYN ® technologies. About Synaffix Synaffix B.V. is a biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform based on GlycoConnect ® , HydraSpace ® and toxSYN ® technologies, that together enable any company with an antibody to develop proprietary best-in-class ADC products under a single license from Synaffix. The Synaffix platform enables a rapid timeline to clinic due to the established supply chain of technology components. Synaffix holds granted patents to its technology. The business model of Synaffix is target-specific technology out-licensing, as exemplified through its partnered pipeline. Synaffix was fully acquired by Lonza in June 2023. For more information about Synaffix’s ADC platform technology, please visit: https://www.synaffix.com/platform/technology . About SOTIO Biotech SOTIO Biotech (SOTIO) is shaping the future of targeted cancer therapies by translating compelling science into patient benefit. The company is advancing an innovative pipeline of mono- and bispecific solid tumor ADC programs at various stages of preclinical development. The SOTIO pipeline also includes two clinical-stage programs: SOT201, a next-generation PD-1-targeting immunocytokine; and BOXR1030, a metabolically-enhanced CAR-T cell therapy targeting GPC3-expressing tumors. SOTIO is a member of the PPF Group. For more information, please visit the company’s website at www.sotio.com . SOURCE: SOTIO Biotech

HOUSTON, March 12, 2025 /PRNewswire/ -- PranaX Corporation, a pioneer in exosome-based regenerative wellness, proudly announces the appointment of Phillip Maderia as its new Chief Executive Officer. With over three decades of leadership in biopharmaceutical manufacturing, most notably in pioneering exosome production, Phillip brings unparalleled expertise to advance PranaX's mission of leveraging exosomes to enhance quality of life nationwide. Continue Reading Regenerative Biomedical Products company appoints CEO Post this Phillip Maderia PranaX is committed to harnessing the evolving biology of exosomes, nature's cellular messengers, to confer regenerative properties on aging, inflamed, and damaged tissues and organs. The company aims to develop exosomes as natural physician-directed supplements and wellness products, delivering transformative health benefits globally. Phillip joins PranaX from Lonza, where he served as Site Head and exosome Business Leader of the Lexington, MA, manufacturing facility since 2021. At Lonza, he spearheaded the expansion of the exosome business, overseeing a $12M operation and leading the construction of Lonza's first 500L-scale GMP exosome manufacturing process. His strategic vision was instrumental in Lonza's acquisition of Codiak BioSciences' intellectual property and clinical programs in 2023, cementing the company's leadership in the exosome field. Before Lonza, Phillip served as VP Manufacturing Operations at Codiak BioSciences where he led the supply of three exosome clinical programs in oncology, and at LFB-USA and Sanofi Genzyme, where he held senior roles in manufacturing and engineering leadership in biologics manufacturing. "Phillip's exceptional track record in exosome and biologics manufacturing and his ability to translate complex science into impactful solutions make him the perfect leader for PranaX," said Steven J. Greco, PhD, Founder and Chief Operating Officer of PranaX. "His arrival marks a defining moment as we accelerate our journey to bring exosome-based wellness products to the world." "I'm thrilled to lead PranaX at this exciting juncture," said Phillip. "Exosomes represent a frontier in regenerative wellness, and PranaX's mission to make these benefits widely accessible resonates deeply with me. I look forward to driving our team to deliver natural, science-driven products that empower people to live healthier, more vibrant lives." Under Phillip's leadership, PranaX aims to expand its research pipeline, forge strategic partnerships, and bring its innovative exosome solutions to market, solidifying its role as a global leader in next-generation wellness. About PranaX Corporation PranaX is a regenerative medicine biotechnology company dedicated to harnessing stem cell-derived exosomes to rejuvenate aging, inflamed, and damaged tissues and organs through evidence-based science. The company's overarching mission is to unlock the regenerative properties of exosomes to promote wellness, combat chronic disease, and lead individuals towards healthier, more fulfilling lives. The company's research, development, and manufacturing operations are headquartered within the Levit Green life science campus in Houston, Texas. SOURCE PranaX WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Lonza to develop a GMP-compliant process for Exo–101 manufacturing from its Siena (IT) site Exo–101 has shown safety and efficacy in multiple pre-clinical trials, and is expected to reach patients in 2027 Basel, Switzerland and Cantanhede, Portugal, 11 March 2025 – Exogenus Therapeutics, a Portuguese biotech company, and Lonza, a global development and manufacturing partner to the pharmaceutical and biotech markets, announced today a collaboration to develop Exo-101, Exogenus’ exosome-based lead candidate. Exogenus Therapeutics specializes in the development of healthcare solutions based on extracellular vesicles, including exosomes and other nanotechnologies. The company’s lead product, Exo-101, derived from immunologically privileged cells from umbilical cord blood, has been shown to have regenerative, anti‑inflammatory and immunomodulatory properties in multiple preclinical models and is expected to reach patients in 2027. Its multifactorial mode-of-action, mediated by a cocktail of small RNAs, proteins and anti-inflammatory lipids, provides the foundation for the drug’s therapeutic potential and positive safety profile[1],[2]. Exo-101 targets patients lacking effective treatment options primarily in the areas of tissue regeneration and inflammatory diseases. Under the agreement, Lonza will leverage its expertise in exosome development and analytical services from its Siena (IT) site and dedicate a team of experts to define a GMP-compliant process for Exo-101 production, based on the foundational work of Exogenus Therapeutics[3]. This feasibility effort aims to define the path towards Exo-101 manufacturing for clinical supply. Joana Correia, Co-Founder and CEO, Exogenus Therapeutics, commented: “We are committed to developing innovative, safe and effective therapies in areas of high unmet medical needs, and to establishing new uses for biological waste materials. This collaboration with Lonza will be essential to achieve a robust, GMP-compliant process for Exo-101 manufacturing, as we progress towards clinical studies. We are excited to partner with a like-minded team with shared goals for the future of exosome based technologies.” Davide Zocco, Head of Exosomes Development, Lonza, added: “At Lonza, we continue to pioneer this emerging and promising field of exosomes, leading innovation to provide development and manufacturing services for our partners. This collaboration highlights our market-leading expertise in supporting exosomes and other extracellular vesicle-based products. We look forward to collaborating with Exogenus Therapeutics to advance its lead candidate towards the clinic.” [1] Rodrigues et al, Int. J. Mol. Sci. 2021, 22(18), 9797 [2] Rodrigues et al, Membranes 2021, 11(9), 647 [3] Cardoso et al, STEM CELLS Transl Med. 2021, 10, 910 Exogenus Therapeutics Contact Details team@exogenus-t.com Lonza Contact Details media@lonza.com Disclaimer Certain matters discussed in this media advisory may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this media advisory. All trademarks belong to Lonza and are registered in CH, US and/or EU, or belong to their respective third party owners and are used only for informational purposes. Photo credit: ©Lonza, used under license. Privacy Policy link